Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business

7th US Indication For The JAK Inhibitor, 2nd In IBD

US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira. 

Intestines health. Guts on pink background top view copy space
Rinvoq is now approved in the US for two inflammatory bowel disease indications • Source: Shutterstock

The US Food and Drug Administration approval of AbbVie Inc.’s Rinvoq (upadacitinib) for Crohn’s disease is the drug’s second inflammatory bowel disease (IBD) indication and seventh indication overall, increasing the JAK inhibitor’s revenue potential at a crucial time for the company. Sales for Humira (adalimumab) are in decline with the introduction of the first US biosimilars of the top-seller in AbbVie’s powerhouse immunology franchise, resulting in lower overall revenue for the company in 2023.

AbbVie hopes that combined sales of Rinvoq and the interleukin-23 inhibitor Skyrizi (risankizumab) will eventually fill the Humira revenue deficit....

More from New Products

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

More from Scrip

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.